The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).

This trial is studying a combination of three drugs — pyrotinib, trastuzumab (Herceptin), and taxane chemotherapy — in women with HER2-positive advanced or metastatic breast cancer who have already been treated with trastuzumab and whose cancer has come back. **You may be eligible if...** - You are a woman aged 18–70 - Your breast cancer has been confirmed as HER2-positive (a specific protein that drives cancer growth) - Your cancer has returned or spread after prior trastuzumab-based treatment - You have not had more than 2 previous drug treatment regimens for advanced disease - You have at least one measurable tumor site and are in good enough health to receive treatment **You may NOT be eligible if...** - You have had more than 2 prior chemotherapy regimens for advanced breast cancer - You have known brain metastases that are symptomatic or unstable - You have serious heart problems or a heart function below a safe threshold - You are pregnant or breastfeeding - You have already been treated with pyrotinib or similar drugs Talk to your doctor to see if this trial is right for you.